TABLE 1.
Pharmacogenetic testing and operational workflow for guiding antidepressant therapy
| Process |
Total (n = 17) N (%) |
Stage of implementation | |
|---|---|---|---|
|
Implemented total (n = 13) N (%) |
Planning Total (n = 4) N (%) |
||
| Prior antidepressant treatment required | |||
| No | 15 (88) | 12 (92) | 3 (75) |
| Age of patients eligible for PGx testing | |||
| <18 years | 1 (6) | 0 (0) | 1 (25) |
| ≥18 years | 4 (24) | 4 (31) | 0 (0) |
| No age restriction | 12 (71) | 9 (69) | 3 (75) |
| Type of PGx test a | |||
| Single gene | 7 (41) | 5 (39) | 2 (50) |
| Multigene | 16 (94) | 13 (100) | 3 (75) |
| Method used for genotyping | |||
| Genotyping | 17 (100) | 13 (100) | 4 (100) |
| Sequencing | 3 (18) | 3 (23) | 0 (0) |
| Testing payment method | |||
| Patient/self‐pay | 12 (71) | 8 (62) | 4 (100) |
| Insurance/third party billed | 11 (65) | 10 (77) | 1 (25) |
| Research funded | 7 (41) | 5 (39) | 2 (50) |
| Other | 3 (18) | 3 (23) | 0 (0) |
| Genes used to guide antidepressant therapy | |||
| CYP2C19 | 16 (100) b | 13 (100) | 3 (100) c |
| CYP2D6 | 15 (94) b | 12 (92) | 3 (100) c |
| Other | 5 (39) b | 5 (39) | 0 (0) |
| Established institutional workflow for ordering and return of results | |||
| Yes | 12 (71) | 10 (77) | 2 (50) |
| Results reported as discrete data | |||
| Yes | 11 (65) | 9 (69) | 2 (50) |
| Clinical decision support available for prescribing decisions | |||
| Consultation | 12 (71) | 10 (77) | 2 (50) |
| PDF report | 11 (65) | 9 (69) | 2 (50) |
| Electronic CDS | 9 (53) | 8 (62) | 1 (25) |
| None | 1 (6) | 0 (0) | 1 (25) |
| Other | 1 (6) | 1 (8) | 0 (0) |
| Results used to guide other therapies in addition to antidepressants | |||
| Yes | 10 (59) | 9 (69) | 1 (25) |
Abbreviations: CDS, clinical decision support; PGx, pharmacogenetic; PDF, portable document format.
a
Sites could select more than one option.
b
Out of 16 sites.
c
Out of 3 sites.